{"disease":{"id":"chronic-hepatitis","name":"chronic hepatitis"},"drugs":{"marketed":[{"drug_id":"eltrombopag","indication_name":"Thrombocytopenia in Chronic Hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"tenofovir-disoproxil-fumarate","indication_name":"Chronic Hepatitis B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TENOFOVIR DISOPROXIL FUMARATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":34,"revenue":null,"mechanism":null},{"drug_id":"sovaldi","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sovaldi","company_name":"Genuine Research Center, Egypt","drug_phase":"marketed","molecular_target":"Cereblon isoform 4, Genome polyprotein, NS5","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"interferon-alfa-2b","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intron A","generic_name":"INTERFERON ALFA-2B","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Interferon alpha","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"interferon-alfa-2b","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intron A","generic_name":"INTERFERON ALFA-2B","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Interferon alpha","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"beclabuvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BECLABUVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"lamivudine","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epivir","generic_name":"LAMIVUDINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Deoxycytidine kinase","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]","quality_score":66,"revenue":null,"mechanism":"Epivir works by mimicking the building blocks of DNA to prevent the replication of viral genetic material."},{"drug_id":"boceprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Victrelis","generic_name":"BOCEPREVIR","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Chymase","drug_class":"Hepatitis C Virus NS3/4A Protease Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"grazoprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zepatier","generic_name":"GRAZOPREVIR","company_name":"Merck & Co.","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Zepatier blocks the NS3/4A protease enzyme, preventing the hepatitis C virus from replicating."},{"drug_id":"adefovir-dipivoxil","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hepsera","generic_name":"ADEFOVIR DIPIVOXIL","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"DNA polymerase subunit gamma-1","drug_class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor","quality_score":64,"revenue":null,"mechanism":"Hepsera works by mimicking a building block of DNA, which it uses to trick the Hepatitis B Virus into incorporating faulty genetic material, ultimately halting its replication."},{"drug_id":"daklinza","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daklinza","company_name":"Genuine Research Center, Egypt","drug_phase":"phase_1","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Genome polyprotein, Nonstructural protein 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"peginterferon","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Peginterferon","company_name":"Ziv Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"peginterferon","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Peginterferon","company_name":"Ziv Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"Interferon beta [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"viread","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Viread","company_name":"Replicor Inc.","drug_phase":"marketed","molecular_target":"Gag-Pol polyprotein, Reverse transcriptase/RNaseH","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"pegasys","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pegasys","company_name":"Zealand University Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"pegasys","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pegasys","company_name":"Zealand University Hospital","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"clevudine","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levovir","generic_name":"CLEVUDINE","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"clevudine","quality_score":null,"revenue":null,"mechanism":"Levovir works by inhibiting viral DNA synthesis, specifically targeting the hepatitis B virus."},{"drug_id":"adefovir","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ADEFOVIR","company_name":"","drug_phase":"discontinued","molecular_target":"DNA polymerase subunit gamma-1, Capsid protein, Protein P","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Adefovir is an antiviral medication used to treat chronic hepatitis B in adults and adolescents, with common side effects including fatigue, headache, and stomach pain."},{"drug_id":"sebivo","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sebivo","company_name":"Ziv Hospital","drug_phase":"phase_1","molecular_target":"Capsid protein, Protein P","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"baraclude","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Baraclude","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Capsid protein, Protein P, Protein P","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"baraclude","indication_name":"Lamivudine-Refractory Chronic Hepatitis B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Baraclude","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Capsid protein, Protein P, Protein P","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"ritonavir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvir","generic_name":"ritonavir","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C9","drug_class":"Cytochrome P450 3A Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Norvir works by blocking the cytochrome P450 3A enzyme, which helps increase the levels of other medications in the body."},{"drug_id":"entecavir","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baraclude","generic_name":"ENTECAVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"entecavir","quality_score":70,"revenue":null,"mechanism":"Entecavir works by inhibiting the replication of the hepatitis B virus."},{"drug_id":"entecavir","indication_name":"Lamivudine-Refractory Chronic Hepatitis B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baraclude","generic_name":"ENTECAVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"entecavir","quality_score":70,"revenue":null,"mechanism":"Entecavir works by inhibiting the replication of the hepatitis B virus."},{"drug_id":"elbasvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zepatier","generic_name":"ELBASVIR","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Hepatitis C Virus NS5A Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Zepatier works by blocking the NS5A protein of the hepatitis C virus, preventing it from replicating."},{"drug_id":"daclatasvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daklinza","generic_name":"DACLATASVIR","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Hepatitis C Virus NS5A Inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bulevirtide","indication_name":"Chronic infection caused by Hepatitis D virus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hepcludex","generic_name":"BULEVIRTIDE","company_name":"MYR GmbH","drug_phase":"marketed","molecular_target":"Sodium/bile acid cotransporter","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"bulevirtide","indication_name":"Chronic viral hepatitis B with hepatitis D","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hepcludex","generic_name":"BULEVIRTIDE","company_name":"MYR GmbH","drug_phase":"marketed","molecular_target":"Sodium/bile acid cotransporter","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"glecaprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mavyret","generic_name":"GLECAPREVIR","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"","drug_class":"Hepatitis C Virus NS5A Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Mavyret works by blocking the NS3/4A protease enzyme, preventing the hepatitis C virus from replicating."},{"drug_id":"asunaprevir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunvepra","generic_name":"ASUNAPREVIR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"dasabuvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viekira Pak (Copackaged)","generic_name":"DASABUVIR","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Protein cereblon","drug_class":"Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"norvir","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Norvir","company_name":"Saint Michael's Medical Center","drug_phase":"marketed","molecular_target":"UDP-glucuronosyltransferase 1-1, Cytochrome P450 2C9, Multidrug and toxin extrusion protein 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ribavarin","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ribavarin","company_name":"Charles University, Czech Republic","drug_phase":"discontinued","molecular_target":"Cytosolic purine 5'-nucleotidase, Adenosine kinase, Ectonucleotide pyrophosphatase/phosphodiesterase family member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"hepsera","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hepsera","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"DNA polymerase subunit gamma-1, Capsid protein, Protein P","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"peginterferon-alfa-2a","indication_name":"Chronic hepatitis C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pegasys","generic_name":"PEGINTERFERON ALFA-2A","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"peginterferon-alfa-2a","indication_name":"Chronic type B viral hepatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pegasys","generic_name":"PEGINTERFERON ALFA-2A","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (genotype 1)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (treatment-naïve and treatment-experienced)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-75-mg","indication_name":"Chronic hepatitis C (Japanese population)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 75 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odv-25-mg","indication_name":"Chronic Hepatitis C (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ODV 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."},{"drug_id":"odalasvir-25-mg","indication_name":"Chronic hepatitis C virus infection (genotypes 1–6)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Odalasvir 25 mg","company_name":"Janssen Research & Development, LLC","drug_phase":"discontinued","molecular_target":"Hepatitis C virus NS5A protein","drug_class":"Direct-acting antiviral (DAA); NS5A inhibitor","quality_score":null,"revenue":null,"mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly."}],"offLabel":[],"totalMarketed":36,"totalPipeline":5},"trials":{"data":[{"nct_id":"NCT03108794","title":"A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B","phase":"","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT06596213","title":"Hepatitis Inequalities Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT04896255","title":"Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B","phase":"","overall_status":"RECRUITING","enrollment_count":33000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT06248580","title":"Find HDV and Determine Its Status in Turkey","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Yaşar Bayındır, MD","has_results":false},{"nct_id":"NCT06966908","title":"Hospital-Based Management of Patients With Chronic Hepatitis B Virus Infection","phase":"","overall_status":"RECRUITING","enrollment_count":16300,"lead_sponsor_name":"Third Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07169656","title":"Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT00388674","title":"Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","phase":"","overall_status":"COMPLETED","enrollment_count":12522,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT04301908","title":"A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and Cirrhosis","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Beijing Ditan Hospital","has_results":false},{"nct_id":"NCT06627608","title":"Treatment Prioritisation and Cost-Effectiveness Analysis for HBV Cure - Real-World Evidence from a Territory-Wide Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT07537387","title":"A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Interferon Treatment Using Pegylated Interferon Alpha","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"xieqing","has_results":false},{"nct_id":"NCT07258251","title":"Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"The Task Force for Global Health","has_results":false},{"nct_id":"NCT05181956","title":"Testing and Epidemiology of Delta Hepatitis","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Asian Pacific Liver Center at Coalition of Inclusive Medicine","has_results":false},{"nct_id":"NCT05813691","title":"Epidemiology of Occult Hepatitis C Virus Infection in Patients Born Before 1969 in the Hospital Setting: a Spontaneous Opportunistic Screening Initiative.","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05062967","title":"Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":3257,"lead_sponsor_name":"Maimónides Biomedical Research Institute of Córdoba","has_results":false},{"nct_id":"NCT03215732","title":"Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal","phase":"","overall_status":"COMPLETED","enrollment_count":3119,"lead_sponsor_name":"ANRS, Emerging Infectious Diseases","has_results":false},{"nct_id":"NCT02629172","title":"Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1","phase":"","overall_status":"COMPLETED","enrollment_count":3043,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03642340","title":"A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"IlDong Pharmaceutical Co Ltd","has_results":false},{"nct_id":"NCT02250001","title":"Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C","phase":"","overall_status":"COMPLETED","enrollment_count":2974,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06638320","title":"Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2452,"lead_sponsor_name":"Tam Anh Research Institute","has_results":false},{"nct_id":"NCT05721300","title":"Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2215,"lead_sponsor_name":"Zhongshan Hospital (Xiamen), Fudan University","has_results":false},{"nct_id":"NCT00781105","title":"Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07298577","title":"Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT06779864","title":"Molecular Characteristics of Hepatitis B Virus Integration, Mutation, and Drug Resistance","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT03777969","title":"Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT06926647","title":"A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false},{"nct_id":"NCT07520123","title":"Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatitis B Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04672915","title":"Prevalence of Occult Hepatitis B Virus Infection（OBI） in Subjects With Chronic Hepatitis B（CHB） Family History","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT03792919","title":"Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Humanity & Health Medical Group Limited","has_results":false},{"nct_id":"NCT07274345","title":"Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Amira Mohamed Zidan","has_results":false},{"nct_id":"NCT03357822","title":"A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT00913757","title":"A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area","phase":"","overall_status":"COMPLETED","enrollment_count":1871,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05423834","title":"Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT02219490","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1596,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT06368882","title":"Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT07203118","title":"A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1444,"lead_sponsor_name":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","has_results":false},{"nct_id":"NCT07476703","title":"Expanded Studies on the SCAPIS Stockholm Reexamination Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Danderyd Hospital","has_results":false},{"nct_id":"NCT02578693","title":"Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)","phase":"","overall_status":"COMPLETED","enrollment_count":1210,"lead_sponsor_name":"Humanity and Health Research Centre","has_results":false},{"nct_id":"NCT07412236","title":"A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1208,"lead_sponsor_name":"Beijing Continent Pharmaceutical Co, Ltd.","has_results":false},{"nct_id":"NCT01380938","title":"Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1150,"lead_sponsor_name":"Casa Sollievo della Sofferenza IRCCS","has_results":false},{"nct_id":"NCT06874127","title":"Non-Invasive Model for Fibrosis Regression in HBV Patients","phase":"","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT02019966","title":"A Korean Cohort Study of TDF Rescue Therapy for Difficult-to-treat CHB Patients: a Comparison Between TDF Monotherapy and TDF-based Combination Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":1020,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04301882","title":"An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Beijing Ditan Hospital","has_results":false},{"nct_id":"NCT05766449","title":"Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT04071353","title":"Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Beijing Ditan Hospital","has_results":false},{"nct_id":"NCT03693586","title":"Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Hospital General de Mexico","has_results":false},{"nct_id":"NCT05630807","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":981,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04387526","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":946,"lead_sponsor_name":"Beni-Suef University","has_results":false},{"nct_id":"NCT06906016","title":"New HBV Infection Biomarkers: Clinical Characterization and Impact on Management","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT01940471","title":"Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":875,"lead_sponsor_name":"Gilead Sciences","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}